Media Articles Related to Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide)
Uncovering Endocrine Causes of Hypertension
Source: Medscape Internal Medicine Headlines [2017.04.21]
Dr Arefa Cassoobhoy highlights one of the week's most important news stories for primary care.
Medscape Internal Medicine
Endocrine Society issues statement to improve detection of curable forms of hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2017.04.10]
A new Scientific Statement issued by the Endocrine Society advises healthcare providers on ways to spot hormonal causes of high blood pressure that can be cured with surgery or treated effectively...
High Blood Pressure (Hypertension)
Source: MedicineNet Polycystic Ovary Specialty [2017.03.31]
Title: High Blood Pressure (Hypertension)
Category: Symptoms and Signs
Created: 1/15/2014 12:00:00 AM
Last Editorial Review: 3/31/2017 12:00:00 AM
New role for immune cells in preventing diabetes and hypertension
Source: Hypertension News From Medical News Today [2017.03.20]
Immune cells which are reduced in number by obesity could be a new target to treat diseases such as type 2 diabetes and hypertension that affect overweight people, according to a collaborative...
Study reveals link between hypertension and brain changes in rats
Source: Hypertension News From Medical News Today [2017.03.10]
New research investigates the changes in brain activity and arterial blood flow that occur with the onset of hypertension in rats.
Published Studies Related to Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide)
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. 
In hypertension and diabetes, early structural changes of the arterial wall precede or support atherosclerosis... The results of this study show that CC and AML treatments may alter identically the natural progression of carotid IMT in hypertensive type 2 diabetic patients.
Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care. 
BACKGROUND AND OBJECTIVE: Fixed-combination tablets of candesartan (orally administered as the pro-drug candesartan cilexetil and hereafter referred to as candesartan) and hydrochlorothiazide (HCTZ) 8/12.5 mg and 16/12.5 mg are effective and well tolerated. However, some patients require higher doses to attain target blood pressure, and combination tablets containing candesartan and HCTZ at the upper end of their respective dose ranges are now being developed. This study aimed to assess the antihypertensive effect and tolerability of the combination of candesartan 32 mg and HCTZ 25 mg versus candesartan 32 mg monotherapy, HCTZ 25 mg monotherapy, and placebo... CONCLUSION: The antihypertensive effect of candesartan/HCTZ 32/25 mg represents fully additive contributions from each of its components, and is generally well tolerated in patients with mild to moderate primary hypertension. This combination adds to the treatment options for improving blood pressure control in patients with hypertension.
Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. [2008.12]
AIM: To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy... CONCLUSION: Candesartan-HCT 32/12.5 mg and candesartan-HCT 32/25 mg are highly effective and provide improved blood pressure reduction and blood pressure control relative to candesartan 32 mg monotherapy, with maintained tolerability, in hypertensive patients whose blood pressure is not optimally controlled with candesartan monotherapy. Furthermore, candesartan-HCT 32/25 mg is more effective than candesartan-HCT 32/12.5 mg in this population.
[Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals] 
INTRODUCTION: In a randomized, phase IV clinical study with 4 parallel treatment arms, the long-lasting treatment effect of candesartan cilexetil (CAS 145040-37-5, CC, Blopress) was to be demonstrated for a repeated therapy-free interval of 48 h in the dosages 8 and 16 mg with or without hydrochlorothiazide 12.5 mg (CAS 58-93-5, HCT; 4 groups totally). The reason for this design was the known possibility of missed tablet doses in the patients' daily practice leading to a not always sufficient lowering of blood pressure in essential hypertension. Therefore, the intake of the daily tablet dose was intentionally omitted twice (after 6 and 8 weeks) during the 8-week study treatment period... CONCLUSIONS: The objectives of the present study were completely met by confirming statistically and clinically the assumption of a clear, long-lasting, safe and metabolically neutral action of CC both for low and high dosages with or without HCT. The intended lowering of blood pressure is effective and well tolerable also repeatedly during the 48-h, therapy-free interval (missed dose trial) which corresponds to a frequent omission of the daily tablet dose and thus well reflects the daily practice in antihypertensive therapeutic regimens.
Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. [2004.12]
OBJECTIVE: To assess efficacy and tolerability of candesartan cilexetil (CC) plus hydrochlorothiazide (HCTZ) fixed combination vs previous monotherapy (PM) plus HCTZ in hypertension... CONCLUSIONS: CC plus HCTZ fixed combination is an effective and safe alternative to other antihypertensive drugs, given either as monotherapy or in combination when they do not satisfactorily control patient's blood pressure.
Clinical Trials Related to Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide)
CKD-330 Drug-Drug Interaction Study (Candesartan) [Completed]
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of
Candesartan between free combination of Candesartan and Amlodipine and Candesartan
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age [Completed]
This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects
ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging
design intended for conduct as a multicenter trial. There are 3 study 'periods': a 1-week
placebo run-in, a 4-week double blind treatment, and a 52-week open-label, long-term
treatment period. Subjects undergo a screening evaluation, then a 1-week single-blind,
placebo run-in, after which eligible subjects are allocated to receive 1 of 3 dose levels of
candesartan cilexetil (0. 05 mg/kg, or 0. 20 mg /kg or 0. 40 mg /kg), liquid formulation, in a
1: 1:1 ratio for 4-weeks. At the end of randomized dose allocation (Day 28), blood pressure
assessment will be performed and subjects may begin the 52-week, open-label treatment period
of the study.
ARIA (Atacand Renoprotection In NephropAthy Pt.) [Completed]
To determine the effective dose of candesartan cilexetil for reduction of urinary protein
excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline
urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in
urinary protein/creatinine ratio from baseline to the end of 28-week treatment
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal [Completed]
The purpose of this study is to evaluate the pharmacokinetic interaction of test
formulations of candesartan and felodipine in a combination package comparing with the
fasting intake of commercial formulations of both Atacand ® and Splendil®
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo [Completed]
The aim is to compare the blood pressure lowering effect of the combination of candesartan
cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32
mg alone, HCT 25 mg alone and placebo in hypertensive adults.
Reports of Suspected Atacand HCT (Candesartan Cilexetil / Hydrochlorothiazide) Side Effects
Drug Ineffective (77),
Blood Pressure Increased (57),
Drug Dose Omission (44),
Cerebrovascular Accident (25),
Blood Pressure Inadequately Controlled (21),
Oedema Peripheral (21),
Headache (20), more >>